Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AKTX NASDAQ:DCOY NASDAQ:GRDX NASDAQ:NCEL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAKTXAkari Therapeutics$14.81+1.2%$6.63$3.02▼$55.60$16.88M1.33461,301 shs19,877 shsDCOYDecoy Therapeutics$8.22-4.5%$6.18$4.32▼$415.80$4.37M0.56118,740 shs2,058 shsGRDXEntero Therapeutics$6.15-4.9%$2.97$1.08▼$6.93$20.66M1.8132,504 shs51,633 shsNCELNLS Pharmaceutics$3.20-3.6%$2.99$1.83▼$30.80$17.12M0.9479,722 shs3,936 shsThe 7 Hottest IPOs On Wall Street’s 2026 WatchlistMarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAKTXAkari Therapeutics+8.94%-17.86%+167.46%+46.30%-74.15%DCOYDecoy Therapeutics+2.99%+12.84%+45.81%+9.21%+860,999,900.00%GRDXEntero Therapeutics-4.85%+40.35%+156.75%+160.89%+646,999,900.00%NCELNLS Pharmaceutics-4.60%+5.40%-13.77%+17.31%-84.98%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAKTXAkari Therapeutics$14.81+1.2%$6.63$3.02▼$55.60$16.88M1.33461,301 shs19,877 shsDCOYDecoy Therapeutics$8.22-4.5%$6.18$4.32▼$415.80$4.37M0.56118,740 shs2,058 shsGRDXEntero Therapeutics$6.15-4.9%$2.97$1.08▼$6.93$20.66M1.8132,504 shs51,633 shsNCELNLS Pharmaceutics$3.20-3.6%$2.99$1.83▼$30.80$17.12M0.9479,722 shs3,936 shsThe 7 Hottest IPOs On Wall Street’s 2026 WatchlistMarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAKTXAkari Therapeutics+8.94%-17.86%+167.46%+46.30%-74.15%DCOYDecoy Therapeutics+2.99%+12.84%+45.81%+9.21%+860,999,900.00%GRDXEntero Therapeutics-4.85%+40.35%+156.75%+160.89%+646,999,900.00%NCELNLS Pharmaceutics-4.60%+5.40%-13.77%+17.31%-84.98%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAKTXAkari Therapeutics 2.25Hold$89.00500.95% UpsideDCOYDecoy Therapeutics 2.00Hold$30.00264.96% UpsideGRDXEntero Therapeutics 0.00N/AN/AN/ANCELNLS Pharmaceutics 1.00SellN/AN/ACurrent Analyst Ratings BreakdownLatest DCOY, GRDX, NCEL, and AKTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/28/2026DCOYDecoy Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (E+) ➝ Sell (E)5/7/2026DCOYDecoy Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E) ➝ Sell (E+)4/22/2026DCOYDecoy Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (E+) ➝ Sell (E)4/20/2026AKTXAkari Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/8/2026AKTXAkari Therapeutics Maxim GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Hold4/1/2026AKTXAkari Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$27.00(Data available from 6/3/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAKTXAkari TherapeuticsN/AN/AN/AN/A$24.75 per shareN/ADCOYDecoy TherapeuticsN/AN/AN/AN/A$11.07 per shareN/AGRDXEntero Therapeutics$40K516.60N/AN/A$7.42 per share0.83NCELNLS PharmaceuticsN/AN/AN/AN/A$1.59 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAKTXAkari Therapeutics-$17.30MN/AN/AN/AN/AN/A-123.29%-63.01%8/18/2026 (Estimated)DCOYDecoy Therapeutics-$12.52M-$106.90N/AN/AN/AN/A-395.42%-193.30%N/AGRDXEntero Therapeutics-$6.39M-$1.88N/AN/AN/AN/A-49.81%-11.02%N/ANCELNLS Pharmaceutics-$8.30MN/AN/AN/AN/AN/AN/AN/AN/ALatest DCOY, GRDX, NCEL, and AKTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/27/2026Q1 2026GRDXEntero TherapeuticsN/A-$0.82N/A-$0.82N/A$0.04 million5/20/2026Q1 2026AKTXAkari Therapeutics-$1.33-$688.00-$686.67N/AN/AN/A5/8/2026Q1 2026DCOYDecoy TherapeuticsN/A-$4.18N/A-$4.18N/AN/A5/1/2026Q4 2025GRDXEntero TherapeuticsN/A-$1.88N/A-$1.88N/AN/A3/31/2026Q4 2025DCOYDecoy TherapeuticsN/A$43.10N/A$43.10N/AN/A3/30/2026Q4 2025AKTXAkari Therapeutics-$0.03-$2.68-$2.65-$2.6650N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAKTXAkari TherapeuticsN/AN/AN/AN/AN/ADCOYDecoy TherapeuticsN/AN/AN/AN/AN/AGRDXEntero TherapeuticsN/AN/AN/AN/AN/ANCELNLS PharmaceuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAKTXAkari TherapeuticsN/A0.270.27DCOYDecoy TherapeuticsN/A1.841.84GRDXEntero TherapeuticsN/A0.160.16NCELNLS PharmaceuticsN/A0.760.76Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAKTXAkari Therapeutics5.06%DCOYDecoy Therapeutics11.88%GRDXEntero Therapeutics12.30%NCELNLS PharmaceuticsN/AInsider OwnershipCompanyInsider OwnershipAKTXAkari Therapeutics30.70%DCOYDecoy Therapeutics0.30%GRDXEntero Therapeutics0.75%NCELNLS Pharmaceutics16.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAKTXAkari Therapeutics91.14 million793,000Not OptionableDCOYDecoy Therapeutics20532,000530,000N/AGRDXEntero Therapeutics93.36 million3.34 millionN/ANCELNLS Pharmaceutics65.35 million4.47 millionNot OptionableDCOY, GRDX, NCEL, and AKTX HeadlinesRecent News About These CompaniesNewCelX Ltd. Submits Pre-IND Package to the FDA for NCEL-101 for the Treatment of Type 1 DiabetesMay 27, 2026 | globenewswire.comNewcelX Reports Financial Results for 2025 and Provides Shareholders with Update on Accelerated Development of Type 1 Diabetes Treatment in Collaboration with Eledon Pharmaceuticals in 2026April 30, 2026 | globenewswire.comMichel Revel Purchases 54,545 Shares of NLS Pharmaceutics (NASDAQ:NCEL) StockApril 30, 2026 | insidertrades.comNewcelX Updates Corporate Presentation to Highlight Type 1 Diabetes Flagship Program Following Strategic Collaboration with Eledon Pharmaceuticals Ahead of Swiss Biotech ConferenceApril 20, 2026 | globenewswire.comNewcelX Announces Pricing of $1.35 Million Equity Financing at 30% Premium PricingApril 1, 2026 | globenewswire.comNewcelX Announces Strategic Collaboration with Eledon Pharmaceuticals to Advance NCEL-101 Program for Type 1 DiabetesMarch 9, 2026 | prnewswire.comNewcelX Reports Peer-Reviewed Publication Supporting Mazindol IR/SR and Advances CVR Monetization StrategyFebruary 12, 2026 | prnewswire.comNewcelX Announces Updated Corporate Presentation Ahead of Key Spring 2026 Investor and Partnering ConferencesJanuary 29, 2026 | prnewswire.comNewcelX Announce Positive Results from International Collaborative Study Exploring Advanced Biomaterial Approaches for Stem Cell-Derived Islet Delivery in Type 1 Diabetes Without Immune SuppressionJanuary 12, 2026 | prnewswire.comNewcelX Appoints Dr. Julien Boisdron, a Swiss Big Pharma Leader in Diabetes Innovation, to Its Scientific Advisory BoardJanuary 5, 2026 | prnewswire.comNewcelX Expands Intellectual Property Footprint with Publication of DOXA Patent Application in ChinaDecember 11, 2025 | prnewswire.comNewCelX Appoints EY as New Auditor Following MergerNovember 20, 2025 | tipranks.comNewcelX Strengthens Scientific Advisory Board with Appointment of Jeremy Shefner, MD, PhD, Chief Medical Officer at the Barrow Neurological InstituteNovember 17, 2025 | prnewswire.comNewcelX Announces Scientific Leadership with the Head of Division of Medical Neurosciences at the Department of Neurology at Hadassah, Prof. Tamir Ben-Hur on Its Scientific Advisory BoardNovember 6, 2025 | prnewswire.comNewcelX Ltd.November 5, 2025 | cnn.comNewcelX Ltd.: NewcelX Provides Business and Strategic Roadmap Update Following Closing of Merger with NLS Pharmaceutics Ltd.November 4, 2025 | finanznachrichten.deNewcelX Unveils Strategic Roadmap Post-Merger with NLS PharmaceuticsNovember 4, 2025 | msn.comNewcelX Provides Business and Strategic Roadmap Update Following Closing of Merger with NLS Pharmaceutics Ltd.November 4, 2025 | finance.yahoo.comNewcelX CEO Issues Letter to ShareholdersNovember 4, 2025 | prnewswire.comNLS Pharmaceutics AG trading halted, news pendingOctober 31, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeDCOY, GRDX, NCEL, and AKTX Company DescriptionsAkari Therapeutics NASDAQ:AKTX$14.81 +0.18 (+1.23%) As of 12:44 PM EasternAkari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration. The company is based in London, the United Kingdom.Decoy Therapeutics NASDAQ:DCOY$8.22 -0.39 (-4.53%) As of 10:01 AM EasternSalarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds; HLB Life Sciences to develop, produce, manufacture, use, and sell the drug in South Korea; and Cancer Prevention and Research Institute of Texas for product development activities, as well as a research partnership with the Cancer Epigenetics Institute at Fox Chase Cancer Center to identify new indications and biomarkers for SP-2577. The company is headquartered in Houston, Texas.Entero Therapeutics NASDAQ:GRDX$6.15 -0.32 (-4.95%) As of 12:15 PM EasternEntero Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of targeted and orally delivered therapies for the treatment of patients with gastrointestinal diseases. The company's pipeline candidates include latiglutenase, a targeted oral biotherapeutic for celiac disease designed to breakdown gluten into non-immunogenic peptides, currently under Phase 2 studies; and capeserod, a selective 5-HT4 receptor partial agonist under Phase 1 studies for the treatment of gastroparesis. It is also involved in the development of adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients, currently under Phase 2 studies for the treatment of exocrine pancreatic insufficiency in patients with cystic fibrosis and chronic pancreatitis; and niclosamide, an oral small molecule with anti-inflammatory inhibitor therapy, currently under Phase 2 studies for the treatment of ulcerative proctitis and ulcerative proctosigmoiditis, as well as immune checkpoint inhibitor-associated colitis and diarrhea in metastatic cancer patients. The company was formerly known as First Wave BioPharma, Inc. and changed its name to Entero Therapeutics, Inc. in May 2024. Entero Therapeutics, Inc. was incorporated in 2014 and is based in Boca Raton, Florida.NLS Pharmaceutics NASDAQ:NCEL$3.20 -0.12 (-3.61%) As of 12:28 PM EasternNLS Pharmaceutics AG, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for patients with rare and complex central nervous system disorders. The company is focusing on the development of treatments for narcolepsy, idiopathic hypersomnia, and other rare sleep disorders, as well as neurodevelopmental disorders, such as attention deficit hyperactivity disorder (ADHD). Its lead product candidates include Quilience to treat excessive daytime sleepiness and cataplexy; and Nolazol for the treatment of ADHD. The company also developing NLS-4, a selective dopamine reuptake inhibitor to prevent rare sleep disorders; NLS-3, a repurposed reverse ester of methylphenidate for treatment of ADHD; NLS-8, a melatonin ML1A receptor agonist, improved scopolamine-induced amnesia; NLS-11, a norepinephrine and dopamine reuptake inhibitor and muscarinic M1, M2, M3 receptor antagonist; and NLS-12, a norepinephrine and dopamine reuptake inhibitor and muscarinic M4 receptor antagonist. NLS Pharmaceutics AG was incorporated in 2015 and is based in Zurich, Switzerland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Microsoft Build 2026 Is Really Just One Big AI Stress Test Slice of the Pie: Why Yum’s Deal Lifts QSR Urban Outfitters Stock Stalls Despite Another Strong Quarter Marvell Stock Soars on NVIDIA's Trillion-Dollar Nod MongoDB Is the Latest SaaS Apocalypse Victim to Say "Not Today" Dollar General Signals Reversal With 60% Rebound Potential Kohl's Stock Soars After Better-Than-Feared Quarter Credo Technologies Paved a Path to a $300 Price Point Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
